What's Happening?
Charles River Laboratories International, Inc. has released findings from a retrospective analysis published in Regulatory Toxicology and Pharmacology, demonstrating the effectiveness of virtual control groups (VCGs) in toxicology studies. The analysis,
which reviewed 20 studies, found that VCGs can maintain scientific integrity while reducing the need for animal models. The studies showed 100% concordance in the No Observed Adverse Effect Level (NOAEL) between VCGs and traditional concurrent control groups (CCGs), with minor endpoint-level variability. This initiative is part of Charles River's Alternative Methods Advancement Project, which aims to reduce animal use in research. The company is collaborating with clients and regulatory bodies to refine these models and promote their adoption.
Why It's Important?
The adoption of VCGs represents a significant shift in toxicology research, potentially reducing the ethical concerns and costs associated with animal testing. By maintaining scientific rigor while minimizing animal use, VCGs align with the 3Rs principle (replacement, reduction, refinement) in research. This approach not only enhances the efficiency of studies but also meets evolving regulatory expectations. The initiative could lead to faster drug development processes, benefiting pharmaceutical companies and patients by accelerating the availability of new therapies. The collaboration with regulatory agencies is crucial for gaining acceptance and confidence in these methods, paving the way for broader industry adoption.
What's Next?
Charles River is actively working with the VICT3R Project, a consortium aimed at integrating VCGs into mainstream toxicology. The project seeks to build a comprehensive database and establish frameworks for the widespread use of VCGs. The European Medicines Agency's draft qualification for VCGs in certain studies marks a step towards regulatory acceptance. Continued collaboration with regulatory bodies will be essential to define standards and acceptable use cases, ultimately supporting the validation and adoption of VCGs across the industry.
